# Givaudan

Company radar · 1,984 documents · 2021-01-01–2026-10-16 · updated 2026-10-19

Canonical: https://slate.greyb.com/radar/givaudan/innovations

## In one minute

### The odorant estate has become a process estate
The Ambrox route is the clearest case. The molecule is settled: (−)-Ambrox made from fermentation-derived (E)-β-farnesene through (E,E)-homofarnesol and an engineered squalene-hopene cyclase, described by the company as an industrial-scale route with better atom and step economy than the sclareol synthesis. What the filings since then protect are the fragile points around it.

Double-bond geometry first. One filing makes (3E,7E)-homofarnesol without the C3 isomerisation the older alkali reflux step produced [1]; another distils the intermediate with 0.1–6 wt% base in the mixture to hold the E/Z ratio [2]. Then enzyme productivity: cyclase variants that take conversion from the wild type's roughly one-tenth to complete [3], with further substitutions still arriving [4].

Then the physical form, which is where the line stops being chemistry. One filing claims the crystal itself — X-ray peaks, elongate crystals of 10–400 µm, colour coordinates of L* ≥ 90 and b* < 8 — because a crystal that size separates from the broth by filtration or decantation instead of extraction [5]. Two others replace recrystallisation with washing: aqueous acid, aqueous surfactant, optional alkali, to at least 95% purity, without the ethanol and the yield loss [6] [7]. These are the filings a company makes when a route is heading for a plant.

1. [US12723012B2](/?paper=US12723012B2&utm_source=radar&utm_medium=dashboard)
2. [MX419261B](/?paper=MX419261B&utm_source=radar&utm_medium=dashboard)
3. [BR122024004207A2](/?paper=BR122024004207A2&utm_source=radar&utm_medium=dashboard)
4. [US2026043058A1](/?paper=US2026043058A1&utm_source=radar&utm_medium=dashboard)
5. [EP4711360A1](/?paper=EP4711360A1&utm_source=radar&utm_medium=dashboard)
6. [US2026062725A1](/?paper=US2026062725A1&utm_source=radar&utm_medium=dashboard)
7. [BR112023001441A2](/?paper=BR112023001441A2&utm_source=radar&utm_medium=dashboard)

### Growth in the regions is being bought as well as built
The largest single move is the agreement to take a 70% stake in Eurofragance, the Barcelona fine-fragrance house. The Moroccan competition authority's notice of the concentration, published in July 2026, describes Givaudan acquiring exclusive control through 70% of the share capital and voting rights. Givaudan's own announcement puts Eurofragance's business at roughly CHF 185 million of incremental 2025 sales on a proforma basis, with closing subject to regulatory approval. The Casablanca development hub follows the same logic: opened in September 2026 with application and perfumery laboratories and a commercial team for the Maghreb and West Africa.


### The defensible asset has moved off the molecule
Across the areas, the filings claim formulations, carriers and methods rather than new ingredients. A precursor's worth is its release chemistry; an active's worth is the carrier that gets it into the skin, in this case hyaluronic acid absorbed into activated smectite clay; a colourant's worth is the complex that holds it stable; a sweetener's worth is the modifier library around it, claimed as a narrow dose window rather than a molecule.


### The cyclase is a platform, and it is being pointed at other molecules
Amberketal is the second target. An enzyme-mediated route cyclises an acyclic acetate and then hydrolyses it. The substrate side is being rebuilt too: selective epoxidation of β-farnesene's 1,3-diene with a metal-salen or porphyrin catalyst, a route through an epoxide mixture to acetylmethylfarnesol and hydroxy-farnesylacetone, and a protected hydroxyfarnesylacetonate that releases the cyclisation substrate in situ. The same enzyme class is claimed for 2-oxygenated decalins at high regioisomeric and diastereomeric purity. Where the enzyme does not reach, the estate works on the molecule anyway: sedgeone by allylic oxidation over an iron phthalocyanine catalyst, chosen because the substrate has several oxidation-sensitive sites.


### The launches that reach the market are the delivery ones
The products with a public launch date sit in the delivery lines. Scentaurus Aquamelon, an oxygen-activated precursor for hair care, arrived in June 2026; Scentaurus PolyDoux, a raspberry-vanilla precursor for hair and fabric care, in February 2026 [[https://www.premiumbeautynews.com/en/givaudan-unveils-fruity-gourmand,27135]]. PlanetCaps was extended to personal care in November 2025, and in July 2026 the company took an equity stake in Microcaps, an ETH Zurich spin-off, to work on precision encapsulation for alcohol-free fine fragrance. The pattern is consistent: the market sees the delivery chemistry, and the molecule work behind it stays in the filings.


### Compliance is being built as a capability, not treated as overhead
The legal and compliance side of the business has started appearing as numbers in the accounts rather than as a background condition. The first half of 2026 carried CHF 103 million of non-recurring costs attributed mainly to litigation settlements and provisions, and net income came in at CHF 475 million against a consensus of CHF 554 million, a charge one analyst called "not well anticipated". The operational answer — customs capability, safety management, competition-law hygiene — stays internal, and the tariff thread runs the same way: where duties were recovered, they are repaid to customers, so the company carries the timing and the administrative cost and the customer keeps the relationship.


### The growing part of the fragrance portfolio is release chemistry
Precursors are odourless molecules that release a fragrance on a trigger, and the estate now covers several triggers and several released classes. Unsaturated ethers release aldehydic notes. N-alkyl anthranilates and o-aminoalkylphenones release alkyl anthranilates and aldehydes by spontaneous oxidative cleavage on ambient oxygen, and are claimed as colour-stable where Schiff bases are not. A carbonyl enol ether releases carbonyl enols, alcohols, aldehydes or ketones. Ethers and esters of fragrant alcohols release over days on air and humidity. Homoallyl ethers release vanillin and eugenol without the discolouration the free phenolics cause. Thioether precursors release fruity ketones and carry a suppressant at 0.1–3.0 wt% against the thiol off-odour the chemistry itself generates. The mechanism behind that family has been published: a δ-cleavage of β-alkylthioalkanones in ambient air, proposed as a Pummerer-type rearrangement, releasing β-mercaptoketones that occur naturally in fruit.


### The receptor work is the one piece of science the company markets directly
In November 2025 Givaudan announced what it called a breakthrough in scent receptor research, describing receptors it had unlocked and the sensitivity gains that followed. Trade coverage framed it as mapping twenty human scent receptors and linking that map to perfume creation. The commercial face of the same work is ChériScentz, launched in May 2025 as a design tool for perfumers. The announcement describes what the work enables; the assay and the screening method underneath it are not part of the public story.


## Overview


The work in these documents points one way. Across fragrance, taste, delivery, actives and bioproduction, the invention has moved off the molecule and onto the system around it: the chemistry that releases a known odorant, the carrier that gets an active into the skin, the complex that holds a commodity pigment stable, the process that makes a settled molecule at scale, and the evidence file that lets a claim be made. The molecules themselves are increasingly ones the industry already has.


## Research

### The capsule is being rebuilt and re-shipped at the same time
Two things are changing at once. The shell is moving off synthetic thermosets: a cross-linked protein coacervate using dihydroxyacetone as the cross-linker, a silk protein shell driven to beta-sheet at the oil-water interface by a humectant, a shell polymerised in place by an enzyme, a Michael-addition shell built from a biodegradable polyester polyol and an α,β-unsaturated acid chloride, filed with CNRS and the University of Montpellier, and a bio-based surfactant–aminosilane–hydrocolloid–epoxy system. One filing goes as far as using Hansen solubility parameters to match the oil phase to the shell building blocks, so the same shell chemistry works whatever is being encapsulated.


### A biodegradable shell is itself a nutrient
This is the problem the rest of the delivery work creates. A shell designed to be eaten by microbes is a food source in an aqueous product, and the capsule can be consumed before the consumer opens the bottle. The answer in the filings is a preservative system that stays out of the capsule: non-partitioning agents — diols, hydroxy esters, carboxylic acids — held in the aqueous phase, defined as less than 25% partitioning into the microcapsules over a month at 25°C, with non-ionic agents at ClogP ≤ 1.0, and surfactants of HLB 12–20 among the options. The filings state the mechanism plainly: the biodegradable encapsulating material is a nutrient source for microbes. This work has no public counterpart — no paper, no launch, no trade coverage — and it is the constraint every biodegradable delivery system in an aqueous product faces.


### The company has published the weak point in its own biodegradability evidence
A shell whose selling point is that it degrades depends on a test that measures degradation, and the company's own study shows how fragile that measurement is. Measured biodegradation of fragrance encapsulates swung from 0% to 91% depending on how the sample was isolated from the slurry before testing, with false positives possible, and the paper proposes a preparation method to get a trustworthy number. Read against the certification claims, that puts the test method inside the product definition: a shell is only as biodegradable as the way it is prepared for the assay.


### The receptor assay is the gate on discovery
The smallest line in the fragrance estate is the enabling method under the rest. Olfactory receptors are hard to express on the surface of lab cells; the filings attach a modified C-terminal motif to the seventh transmembrane helix, which improves trafficking and raises assay sensitivity enough to test poorly soluble or cytotoxic molecules and to find antagonists as well as pleasant ones. The claims point at high-throughput screening, at de-orphanising receptors with no known ligand, and at building uniform receptor libraries for objective profiling. A later filing adds a computer-implemented method for predicting olfactory properties from the same assay.


### In taste, the invention is the combination, and the claims have moved from extracts to numbers
The sweeteners, the rosemary and green coffee extracts, the betanin and the mono- and diglycerides are commodity inputs. What the filings claim is the pairing and the ratio. A mogroside — siamenoside I or its isomer — is combined with aroma ingredients, sweetness modifiers and chlorogenic acids, with the two mechanisms claimed together rather than as alternatives; a dihydrochalcone does the same job from a different starting point; a narrow dose window of 15–50 ppm of mogroside IV, siamenoside and neomogroside is claimed as such. A sweet protein from honey truffle is paired with a positive allosteric modulator of the sweet receptor. Umami is addressed with putrescine bisamides as a non-glutamate alternative for low-salt products, and the off-notes of plant protein with magnesium and calcium chloride at 10–5,000 ppm each or with a Maillard reaction product of an amino acid and a reducing sugar.


### In colour, the pigment is bought and the stabilisation is invented
Givaudan is not inventing pigments here; it is inventing what makes commodity pigments behave like synthetic dyes. A phycobilin is complexed with a protein, polypeptide or peptide to hold it against acid, heat and light. An oil-soluble colorant is encapsulated with whey protein, a milk polysaccharide or a plant protein, by spray drying, to stop oxidation and off-notes. Betanin is stabilised with a salt plus citric, ascorbic or malic acid and EDTA for heat stability. A polyketide pigment is protected from light with a carotenoid, rosmarinic acid, chlorogenic acid, rutin glucoside, cyclodextrin or tocopherol, with synergy claimed between rosmarinic acid and either tocopherol or gamma-cyclodextrin. A genipin-rich extract is paired with a protein-rich extract for a heat-stable blue.


### One yeast chassis, three sugar polymers, and a separate biocatalysis line
One engineering approach is applied three times. A Saccharomyces cerevisiae chassis carries a hyaluronan synthase to build the chain, a UDP-glucose dehydrogenase to supply the activated sugar, and a hyaluronidase with a secretion signal to cut the chain to length and release it. The molecular weight is set by the fermentation rather than by a separate sizing step: cultivation medium pH controls a product between 800 Da and 5 kDa, with a median below 3 kDa. The same chassis is claimed for chondroitin and for heparosan, where promoter choice, pH and fermentation time set a weight between 150 and 1,500 kDa and the process is described as scalable to 250,000 litres as an animal-free alternative to heparin extraction. A fourth molecule, ectoine, comes from the same engineering group.


### The actives line patents the carrier, not the extract
The botanical and marine lines follow one pattern: the extract is described, the delivery is claimed. A gardenia fruit extract is held in a betaine-glycerol-water eutectic at pH 5 or above. A plant extract carrying at least 15 wt% of crenatoside and acteoside is extracted with a water-free solvent and then solvent-exchanged into 1,3-propanediol. A mango leaf extract is supplied in propanediol and water. Marine actives repeat it: a Laminaria hyperborea extract defined by its mannitol, laminaran and fucoidan content, a Himanthalia elongata extract claimed against tyrosinase and for barrier and elasticity endpoints, and a Crocus sativus flower extract claimed against Malassezia species.


### Oral care and deodorant are engineered in filings and absent from the public account
Two lines are engineered in filings and absent from the public account. Oral care: granted claims on structurally distinct TRPM8 cooling agonists that trigger calcium influx in cold-sensitive neurons, and a solvent system — 2-phenylethanol or phenoxyethyl alcohol — that makes the most stable polymorph of one of them usable, identified by its X-ray peaks. The self-confidence filing is the interesting one: a cooling carboxamide, EC180, tasteless and odourless and contributing nothing to breath freshness, is claimed to hold self-reported self-confidence above 80% for up to 60 minutes after brushing. The claim is about a psychological state, measured by a self-reported scale, which makes the measurement method part of the asset.


### The assessment and creation functions are being engineered too
The company is also engineering the functions that decide what it can sell. Skin sensitisation is the clearest case. An industry group including Givaudan has published a route to a point of departure for sensitisation potency using new approach methodologies alone — three defined approaches tested against 110 chemicals, with adjustment factors to convert the result into a no-expected-sensitisation-induction level for quantitative risk assessment. A second paper derives a metabolism factor for salicylate esters by in vitro to in vivo extrapolation, so aggregate exposure to the common metabolite can be estimated from liver S9 data rather than assumed. A third quantifies the estrogenic potency of benzyl salicylate against estradiol and finds a partial agonist active only near cytotoxic concentrations. This is the machinery that lets a restricted material stay in use, or shows that it cannot.


## Market

### Natural ingredients carries both a story and a capital line
The natural-ingredients programme has a public narrative and a price tag. In February 2026 Givaudan committed CHF 55 million to Campus 52 in Grasse as the centre of excellence for its House of Naturals organisation [[https://www.premiumbeautynews.com/en/givaudan-doubles-down-on-natural,27118]]. The sourcing side is presented as a five-year record under Sourcing4Good, covering audits, partnerships and supply-chain practices. The story is told as a sustainability commitment; the capital line makes it a capacity commitment as well.


### The legal thread is the most continuously covered part of the public record
The competition and litigation story has produced a steady run of coverage where the technical lines produce a launch and then go quiet. The US price-fixing litigation has moved through rulings and proposed class settlements. India opened two separate matters, one on anti-poaching agreements and one on price collusion. Where the product story is a series of announcements, the legal story is a series of events the company does not control.


### The company sells tools and mood alongside ingredients
Part of the public account is not an ingredient at all. Myrissi, launched in 2023, translates a scent into a colour pattern for consumer testing. The wellbeing line is sold the same way, as a social and emotional proposition: Message in a Bottle reframes perfume as a social gesture, the company has pitched fragrance as an antidote to loneliness, and in September 2026 it published four olfactory symbols of human connection. These are marketing positions rather than technical claims, and they carry no filing behind them.


### The announced science stops at the result
Where the company does announce science, it announces the outcome. The receptor release describes what the work enables and not how the assay is built. ChériScentz is presented as a tool perfumers use. The method, the screening platform and the molecule chemistry sit in the filings, and the public record does not describe them. That is the shape of the whole public account: the delivery and the region are marketed, and the chemistry underneath them is not.


## Strategy

### Two delivery routes are being run in parallel rather than one displacing the other
Precursor chemistry and encapsulation pull against each other. If a precursor releases the odorant on a trigger the consumer's own use supplies, then how long a fragrance lasts stops depending on the odorant's physical properties, and the competitive ground moves from the molecule to the delivery chemistry. Encapsulation is capital-heavy; precursor chemistry is a molecule made in reactors the company already has.


### The platform is being monetised at the cosmetic end while the drug end is held
The yeast chassis is applied three times, and only one of the three has reached the market. Low-molecular-weight hyaluronic acid is sold as a skin active, and the newest filing claims a weight band below 3 kDa for wrinkles and sleep lines. Chondroitin has filings for a controlled-molecular-weight yeast process and no launched ingredient attached to them.


### Capacity is being committed on long lead times, in specific regions
Givaudan is putting $215 million into a 258,000-square-foot liquids plant at West Harrison on the Indiana–Ohio border, with partial operations planned for 2028, and USD 110 million into a fragrance compounding facility at Pedro Escobedo in Mexico, sized at 20,000–25,000 tonnes and operational during 2029, framed as "in the region, for the region" and tied to the 2030 strategy. Makó in Hungary is being built into a regional production hub on the same logic.


## Areas

- Corporate, Compliance & Operations · 499 documents
- Fragrance Chemistry & Odorants · 435 documents
- Taste & Nutrition Solutions · 413 documents
- Delivery & Encapsulation Systems · 328 documents
- Cosmetic & Personal Care Actives · 280 documents
- Bio-Production & Green Chemistry · 25 documents